PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 20260 citationsOpen Access

Research Progress and Clinical Practice in the Comorbidity Management of Obstructive Sleep Apnea Hypopnea Syndrome and Obesity Hypopnea Syndrome

View Full Paper
LLLinlin LiRGRuixue GengYWYuchen Wang

Key Points

  • The aim is to summarize the current understanding and management strategies for patients with comorbid obstructive sleep apnea-hypopnea syndrome and obesity hypoventilation syndrome.
  • Systematic review of epidemiological characteristics and pathophysiological mechanisms.
  • Analysis of diagnostic criteria and technologies for OSAHS-OHS comorbidity.
  • Evaluation of treatment strategies, including digital therapeutics and metabolic interventions.
  • Examination of challenges in clinical management and unresolved controversies.
  • Comorbid patients face higher cardiovascular risks compared to those with a single syndrome.
  • Chronic intermittent hypoxia contributes to a negative cycle with obesity.
  • Portable monitoring devices enhance screening efficiency for OSAHS-OHS.
  • Digital therapeutics and new metabolic drugs show clinical promise in management.
  • Multidisciplinary approaches are essential but face resource and policy challenges.

Abstract

Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) and Obesity Hypoventilation Syndrome (OHS) are core components of the obesity-related respiratory disease spectrum, and their comorbidity has become a major challenge in the global public health field. This review systematically summarizes the epidemiological characteristics, pathophysiological mechanisms, diagnostic criteria, diagnostic technologies and treatment strategies of OSAHS-OHS comorbidity, with a focus on the cutting-edge progress of digital therapeutics and metabolic intervention, as well as the historical evolution and current status of clinical management. We also conduct an in-depth analysis of the unresolved controversies and practical challenges in the current clinical management of this comorbidity. OSAHS-OHS comorbid patients have a significantly higher risk of cardiovascular complications than those with a single disease, and chronic intermittent hypoxia (CIH) forms a vicious cycle with obesity through multiple pathophysiological pathways. The combination of multi-dimensional assessment tools and portable monitoring devices has improved the screening efficiency of OSAHS-OHS comorbidity, and the selection of respiratory support therapies such as continuous positive airway pressure (CPAP) and non-invasive ventilation (NIV) depends on patient phenotypes. Digital therapeutics and novel metabolic intervention drugs have shown promising clinical value in the management of this comorbidity. The multidisciplinary collaboration model is the key to improving the prognosis of comorbid patients, while current clinical management is still faced with challenges such as policy lag, ethical controversies and uneven resource allocation. Future research should focus on individualized therapeutic targets, the integration of digital technologies and the optimization of health policies to achieve precise and efficient management of OSAHS-OHS comorbidity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6980ffe7c1c9540dea812ca6https://doi.org/10.3390/diagnostics16030444
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea2026
  2. 2Obstructive sleep apnea and comorbidities: a current perspective from diagnosis to treatment2025
  3. 3A Multidisciplinary Approach to Obesity Hypoventilation Syndrome: From Diagnosis to Long-Term Management—A Narrative Review2025 · 2 citations
  4. 4The latest research progress on the relationship between obstructive sleep apnea–hypopnea syndrome and metabolic syndrome2024 · 3 citations
  5. 5Obstructive sleep apnea hypopnea syndrome and metabolic syndrome: A synergistic cardiovascular risk factor2012 · 39 citations